APOB and hydrops fetalis: Proprotein convertase subtilisin/kexin type 9​​​​​​​ (PCSK9) inhibitors (alirocumab, evolocumab) provide substantial reductions in ApoB and LDL-C and are appropriate for high-risk HF patients with residual atherosclerotic risk.